Over the past ten years, the med tech sector has consistently performed well and experienced growth. With 2019 seeing the continuation of this trend, many predicted that further growth for med tech would occur in 2020.
Any mergers and acquisition (M&A) activity in January and February 2020 swiftly came to an end in March and April as the Covid-19 pandemic hit bringing financial instability and uncertainty with it. Indeed Ernst Young (EY)’s Pulse of the industry 2020 report on med tech found that the Covid-19 disruption was most evident in the industry’s M&A performance.
“There is no doubt that it’s slowed down the pace” of med tech M&As, notes EY life science partner John Babitt. EY’s report found that total M&A values fell by 60% from $67.6bn in 2019 to $27.1bn. The average deal value fell from $463m to $167m, according to EY’s figures. This decline was particularly evidence in the second half of the year. According to a report by Evaluate, the average size of completed mergers in the first six months of 2020 was lower than at any point in the past decade.
This situation was not helped by one of the three 2020 mega-deals – those worth over $10bn – falling through. In August, Thermo Fischer Scientific’s $11.5bn offer to acquire Qiagen was refused by the latter’s shareholders who argued the company was worth more.
Where has med tech been hit hardest?
Although general uncertainty and travel restrictions linked to the pandemic has affected all industries, the financial impact of Covid-19 on the med tech industry has been primarily linked to the significant consequence on companies focusing on so-called ‘elective’ procedures. This is emphasised in both EY’s report and PricewaterhouseCoopers (PwC)’s life sciences deals insights midyear 2020 analysis.
Babitt, who prefers the term deferrable to ‘elective’ procedures, notes that they were “draconically” impacted by the pandemic. This is because they are not emergency procedures and can therefore be delayed as more and more hospital beds needed to be reserved for Covid-19 patients. EY’s report also notes that patients were choosing to steer clear of hospitals for non-emergency procedures this year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe report also found that eight companies primarily focused on ‘elective’ procedures saw their revenues fall by at least 15%. These include Envista, Dentsply Sirona and Zimmer Biomet.
As a result, many of these companies “which were going to do deals had no choice to put them on hold, look internally and solidify their own company to weather this storm”, adds PwC US pharma and life sciences leader Glenn Hunzinger.
Not all doom and gloom
Although Covid-19 has had a negative impact on med tech deals and M&As, Lincoln International concludes that med tech is not closed for business. In fact, there are areas of the med tech industry that have flourished because companies have stepped up to help manage and mitigate the Covid-19 crisis.
“Med tech’s work has saved lives, allowed medical facilities to keep running, enabled patients to be treated in hospitals or at home, and overall made it possible for normal operations to be maintained, while simultaneously also helping health systems, governments and the general public wage a global health battle on a scale not previously seen this century,” wrote EY global med tech leader Jim Welch in the report’s introduction.
Although performing worse than pharma in terms of general deal values and volumes, according to PwC’s report, Babitt notes that med tech has outperformed pharma in terms of M&As.
Until Gilead’s announcement it was acquiring Immunomedics for $21bn in September, the pharma field had largely been missing mega M&As. Babitt notes there had been a lot of partnering and initial public offerings, but not a lot of “true M&A”, as he terms it.
Spotlight on digital health and diagnostics
The largest med tech megadeal of 2020 – Teladoc’s acquisition of Livongo for $18.5bn – is also the largest M&A investment ever made in digital health. “With the success of the Livongo-Teladoc deal… everyone is talking about how digital healthcare delivery has really accelerated [during the pandemic]. What might have been on a three-year trajectory has been truncated into about three months,” notes Babitt.
“It may be that the events of 2020 will conclusively demonstrate to med tech and the broader life sciences industry that digital acceleration is needed,” according to EY’s report. The pandemic has caused a rising demand for remote care technology for chronic diseases and general health management as people want to avoid excessive trips to the hospitals and doctors’ surgeries.
In addition, the third of the 2020 megadeals – Siemens Healthineers $16.4bn acquisition of Varian Medical – suggests that more traditional med tech companies are also interested in digital health. This acquisition differs to the first because Teladoc and Livongo are both existing players in the digital health field which have expanded their offerings as a result of the deal.
Siemens Healthineers’ acquisition allows it to build its diagnostics and imaging portfolio and provide access to end-to-end oncology solutions from diagnostics to treatment under one vendor.
Diagnostics is another area that has grown this year, not only despite of Covid-19, but because of the pandemic. EY found that companies focused on diagnostics a rise in revenues due to heightened demand from the pandemic; as of August 2020, 448 Covid-19 related diagnostics were launched or in development. In addition, non-imaging diagnostics was found by EY to be the forefront of the M&A space in 2020.
Med tech’s bright future
After a slow first half, EY see the announcement of the two remaining megadeals – Teladoc-Livongo and Siemens Healthineers-Varian – in August as a possible reversal in the general downward M&A trend. “This raises the prospect that the industry may now be ready to deploy some of its debt-financed firepower in more aggressive M&A deals,” concluded EY.
Babitt also noted that on earnings calls companies are expressing their eagerness to start M&A once again. Companies have found a way to adapt get deals done despite the travel restrictions.
He is optimistic about 2021 because “there are going to be a new crop of business that have been successful during this timeframe” – including those in the digital health space – and their capabilities match well with larger, traditional med tech companies. “We’ve got new opportunities to really double down and turbocharge business… [so] I think we could see some nice activity into 2021”.
Hunzinger also believes there will be large deals and consolidation in 2021. He talks about how important scale remains to the med tech industry, and how this intersects with the wave of innovation in the sector, particularly around technology, that has emerged in 2020 and what means for the future of health.
Lincoln International argues that medical technology will be able to bounce back more rapidly to pre-Covid-19 levels, compared to other industries. Med tech is a good position as 2021 approaches because of its commitments during the Covid-19 pandemic; EY’s report noted that this has raised the industry’s profile and reputation with the public and investors.
